AN2 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	53.49	19.94	21.35	15.65	27.22	12.1
Short-Term Investments	31.8	38.06	62.27	91.65	68.84	46.46
Cash & Short-Term Investments	85.29	58	83.62	107.3	96.06	58.56
Cash Growth	27.18%	-30.64%	-22.07%	11.70%	64.05%	1338.70%
Other Current Assets	2.2	1.94	2.64	3.21	2.51	1.55
Total Current Assets	87.49	59.94	86.26	110.51	98.62	60.11
Net Property, Plant & Equipment	-	-	-	-	0.05	-
Long-Term Investments	-	2.01	5.02	27.19	3.22	3.49
Other Long-Term Assets	-	-	0.8	1.04	0.72	1.72
Total Assets	87.49	61.95	92.09	138.74	102.56	65.32
Accounts Payable	2.62	3.02	3.32	2.68	2.12	1.06
Accrued Expenses	2.38	4.47	6.13	10.7	5.01	2.32
Current Portion of Leases	-	-	-	-	0.05	-
Other Current Liabilities	-	1.23	0.79	0.67	0.01	0.02
Total Current Liabilities	5.56	8.72	10.24	14.04	7.19	3.4
Other Long-Term Liabilities	-	-	-	-	0	0.01
Total Long-Term Liabilities	-	-	-	-	0	0.01
Total Liabilities	5.73	8.89	10.24	14.04	7.19	3.41
Additional Paid-in Capital	332.74	293.95	287.59	278.88	185.47	-
Accumulated Other Comprehensive Income	-0.01	0.06	0.03	0.28	-0.37	-0.03
Retained Earnings	-250.98	-240.95	-205.78	-154.46	-89.72	-47.38
Total Common Shareholders' Equity	81.76	53.06	81.85	124.7	95.37	-47.41
Shareholders' Equity	81.76	53.06	81.85	124.7	95.37	109.32
Total Liabilities & Equity	87.49	61.95	92.09	138.74	102.56	65.32
Total Debt	-	0	0	0	0.05	0
Net Cash (Debt)	85.29	58	83.62	107.3	96.01	58.56
Net Cash Growth	47.05%	-30.64%	-22.07%	11.76%	63.96%	1338.70%
Net Cash Per Share	2.73	1.92	2.80	4.55	6.26	22.20
Book Value	81.76	53.06	81.85	124.7	95.37	-47.41
Book Value Per Share	2.62	1.76	2.74	5.28	6.22	-17.97
Tangible Book Value	81.76	53.06	81.85	124.7	95.37	-47.41
Tangible Book Value Per Share	2.62	1.76	2.74	5.28	6.22	-17.97

SEC Filings: 10-K · 10-Q